 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Course Framing and Scope

WHAT IS YOUR COURSE ABOUT?

SCOPE — Q3A(R2) APPLIES TO:

Q3A(R2) DOES NOT APPLY TO (these have their own guidance):

Impurity Fundamentals and Thresholds

IMPURITY CLASSES:

THE THREE THRESHOLDS (Q3A(R2), Attachment 1):

WHAT EACH THRESHOLD MEANS:

Practical Application and Compliance

SLIDE 3 — CASE STUDY WITH CHARACTERS AND DIALOGUE (90 sec)

SLIDE 4 — PRACTICAL APPLICATION (60 sec)

SECTION E — 10-POINT KEY AUDIT CHECKLIST

Quiz

PART A — QUIZ (5 scenario-based questions)

SLIDE 5 — KNOWLEDGE CHECK + TAKEAWAYS (45 sec)

SECTION B — TEACHING GOALS

SECTION C — REFERENCE FACTS USED IN THIS MODULE (for accuracy)

Key Summary Points

Survey and Feedback

PART B — REFLECTION

PART C — TOP 5 TAKEAWAYS

Welcome to the "Fundamentals of Impurity Reporting and Control Under ICH Q3A(R2)" course. In the highly regulated pharmaceutical industry, ensuring patient safety and product quality is paramount.

Welcome to the "Fundamentals of Impurity Reporting and Control Under ICH Q3A(R2)" course. In the highly regulated pharmaceutical industry, ensuring patient safety and product quality is paramount. A critical component of this mission is the rigorous control of impurities in new drug substances. This comprehensive online course is designed to demystify the ICH Q3A(R2) guidelines, providing you with a clear, actionable understanding of impurity reporting, identification, and qualification.

Whether you are in Quality Assurance (QA), Quality Control (QC), or Manufacturing, navigating the complexities of impurity thresholds can be challenging. This course breaks down the fundamental concepts, starting with the precise definition of an impurity and the overarching scope of the ICH Q3A(R2) preamble. You will learn exactly which chemically synthesized new drug substances fall under this guidance and, equally important, which products—like biologics, peptides, and oligonucleotides—require alternative guidelines.

Dive deep into the three primary impurity classes: organic, inorganic, and residual solvents. Master the critical control thresholds—Reporting, Identification, and Qualification—and understand why a one-size-fits-all approach is scientifically inappropriate. Through engaging case studies, practical application scenarios, and a 10-point key audit checklist, you will learn how to make compliant, risk-based decisions, ensure data integrity, and maintain inspection readiness. By the end of this course, you will be equipped to foster cross-functional collaboration and confidently handle Out of Specification (OOS) or Out of Trend (OOT) results, safeguarding both patient health and your organization's regulatory standing.

101. Fundamentals of Impurity Reporting and Control Under ICH Q3A(R2)

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The presence of impurities in new drug substances presents a significant challenge to pharmaceutical quality, patient safety, and regulatory compliance. Under the ICH Q3A(R2) guideline, an impurity is strictly defined as any component of the new drug substance that is not the chemical entity defined as the drug substance itself. For professionals across Quality Assurance, Quality Control, Manufacturing, Validation, and Regulatory Affairs, mastering the principles of impurity reporting and control is an essential operational requirement. This course establishes a foundational understanding of how disciplined impurity management safeguards actual patient exposure and maintains regulatory standing during both the submission and commercialization phases of a product's life cycle. No prior toxicology knowledge is required, making this an ideal starting point for anyone who generates, reviews, interprets, or makes batch release decisions based on analytical data.</p>

<p>Throughout this program, participants will systematically explore the overarching scope of ICH Q3A(R2), learning to identify which chemically synthesized drug substances are covered and which product types—such as biologicals, peptides, and oligonucleotides—require alternative guidance. The curriculum delves into the three primary impurity classes (organic, inorganic, and residual solvents) and thoroughly examines the critical thresholds for reporting, identification, and qualification tied to maximum daily doses. By engaging with realistic batch-disposition case studies and a comprehensive ten-point audit checklist, cross-functional teams will learn to navigate competing production pressures, apply risk-based decision-making to out-of-specification results, and implement industry best practices that ensure continuous inspection readiness.</p>
        </div>
    </div>
</div>
